Brief: RhoVac: COVID-19 Expected To Further Affect Clinical Phase IIb Study

Chosa Oncology AB

12/10/2020 07:36

Oct 12 (Reuters) - RhoVac AB  RHOVAC.TE :
    * THE COVID-19 PANDEMIC IS EXPECTED TO FURTHER AFFECT
RHOVAC'S
CLINICAL PHASE IIB STUDY
    * COVID-19 PANDEMIC IS EXPECTED TO FURTHER AFFECT RHOVAC'S
CLINICAL PHASE IIB STUDY
    * RECRUITMENT RATE IN SEPTEMBER NOW INDICATES FULL
RECRUITMENT IN
Q2 2021.
    * TO REDUCE EFFECT OF DELAYS CAUSED BY PANDEMIC, NUMBER OF
CLINICS
WILL BE INCREASED
    * STUDY IS STILL EXPECTED TO BE CARRIED OUT WITH EXISTING
FUNDING.

Source text for Eikon:  ID:nWkr6ZbwQb 
Further company coverage:  RHOVAC.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785110;))